X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs BIOCON LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB BIOCON LTD DR. REDDYS LAB/
BIOCON LTD
 
P/E (TTM) x 27.3 36.6 74.5% View Chart
P/BV x 2.8 4.9 57.8% View Chart
Dividend Yield % 1.0 1.5 66.3%  

Financials

 DR. REDDYS LAB   BIOCON LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
BIOCON LTD
Mar-16
DR. REDDYS LAB/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs4,383496 884.2%   
Low Rs2,750397 693.6%   
Sales per share (Unadj.) Rs920.1174.3 528.0%  
Earnings per share (Unadj.) Rs126.144.8 281.4%  
Cash flow per share (Unadj.) Rs183.056.9 321.5%  
Dividends per share (Unadj.) Rs20.005.00 400.0%  
Dividend yield (eoy) %0.61.1 50.0%  
Book value per share (Unadj.) Rs685.8202.8 338.2%  
Shares outstanding (eoy) m170.61200.00 85.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.92.6 151.4%   
Avg P/E ratio x28.310.0 284.1%  
P/CF ratio (eoy) x19.57.8 248.7%  
Price / Book Value ratio x5.22.2 236.4%  
Dividend payout %15.911.2 142.1%   
Avg Mkt Cap Rs m608,48189,220 682.0%   
No. of employees `00021.74.4 490.8%   
Total wages/salary Rs m31,8746,363 500.9%   
Avg. sales/employee Rs Th7,244.47,894.5 91.8%   
Avg. wages/employee Rs Th1,470.91,441.2 102.1%   
Avg. net profit/employee Rs Th992.82,029.7 48.9%   
INCOME DATA
Net Sales Rs m156,97834,854 450.4%  
Other income Rs m2,693845 318.7%   
Total revenues Rs m159,67135,699 447.3%   
Gross profit Rs m34,5878,200 421.8%  
Depreciation Rs m9,7052,423 400.5%   
Interest Rs m824102 807.8%   
Profit before tax Rs m26,7516,520 410.3%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m5,2372,569 203.9%   
Profit after tax Rs m21,5148,961 240.1%  
Gross profit margin %22.023.5 93.7%  
Effective tax rate %19.639.4 49.7%   
Net profit margin %13.725.7 53.3%  
BALANCE SHEET DATA
Current assets Rs m118,20139,932 296.0%   
Current liabilities Rs m68,36816,276 420.1%   
Net working cap to sales %31.767.9 46.8%  
Current ratio x1.72.5 70.5%  
Inventory Days Days6054 112.0%  
Debtors Days Days9786 112.4%  
Net fixed assets Rs m72,26539,101 184.8%   
Share capital Rs m8531,000 85.3%   
"Free" reserves Rs m111,54838,591 289.1%   
Net worth Rs m117,00940,556 288.5%   
Long term debt Rs m10,69020,724 51.6%   
Total assets Rs m200,10484,816 235.9%  
Interest coverage x33.564.9 51.5%   
Debt to equity ratio x0.10.5 17.9%  
Sales to assets ratio x0.80.4 190.9%   
Return on assets %11.210.7 104.5%  
Return on equity %18.422.1 83.2%  
Return on capital %21.619.0 113.8%  
Exports to sales %46.330.7 150.4%   
Imports to sales %9.020.4 43.9%   
Exports (fob) Rs m72,61810,717 677.6%   
Imports (cif) Rs m14,0507,105 197.7%   
Fx inflow Rs m75,40511,789 639.6%   
Fx outflow Rs m27,1158,393 323.1%   
Net fx Rs m48,2903,396 1,422.0%   
CASH FLOW
From Operations Rs m40,4765,264 768.9%  
From Investments Rs m-19,421-9,540 203.6%  
From Financial Activity Rs m-17,00910,867 -156.5%  
Net Cashflow Rs m4,0466,591 61.4%  

Share Holding

Indian Promoters % 25.5 40.4 63.1%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 5.4 8.4 64.3%  
FIIs % 35.3 10.7 329.9%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 19.9 76.9%  
Shareholders   75,885 109,995 69.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 18, 2017 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS